Faron, etusivu

releases and publications

Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025

Faron Pharmaceuticals Ltd: Director Dealing

Insider Transaction Regulatory

Faron Pharmaceuticals Ltd: Director/PCA Dealing

Insider Transaction Regulatory

Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

Insider Transaction Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Next
Back to top